With two billion people overweight or obese and the obesity treatment market expected to reach $200 billion by 2031, Olio Labs has released a groundbreaking study. The data uncover fundamental ...

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...

When you or your bed partner has sleep apnea, a restful night’s sleep can be hard to come by. Treating this common condition ...

A day after announcing a business split-off to focus on weight loss and diabetes implants, Vivani Medical has implanted the ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Novo Nordisk stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its next-generation GLP ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Eli Lilly has reduced the prices of certain Zepbound vials and introduced higher-dose options, making the weight-loss drug ...

Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance. Danish drugmaker Novo Nordisk said Wednesday that it will drop prices 23% for all ...